Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
258 institutional managers report a position in Erasca, Inc. worth $5.3B between them, filed on form 13F for the quarter ending 2026-06-30. 28 of them hold 80% of it, the largest being Frazier Life Sciences Management, L.P. at 8.64%.
233 more managers in the register
28 managers hold 80% of the $5.3B institutional base. The other 230 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
Erasca, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
No intraday reading yet this session.
ERAS (Erasca, Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
via Frazier Life Sciences Management, L.P., T. Rowe Price Investment Management, Inc., Logos Global Management LP +6 more · 8.64% of ERAS, 8.58% of MAZE
via Frazier Life Sciences Management, L.P., Logos Global Management LP, Paradigm Biocapital Advisors LP +5 more · 8.64% of ERAS, 8.98% of ACHV
via RTW Investments, LLC, Paradigm Biocapital Advisors LP, Siren, L.L.C. +10 more · 6.21% of ERAS, 6.49% of TNGX
via VR Adviser, LLC, RTW Investments, LLC, Paradigm Biocapital Advisors LP +7 more · 6.19% of ERAS, 5.57% of ORKA
via T. Rowe Price Investment Management, Inc., RTW Investments, LLC, Caption Management, LLC +4 more · 7.33% of ERAS, 6.69% of CGON
via VR Adviser, LLC, Frazier Life Sciences Management, L.P., Paradigm Biocapital Advisors LP +2 more · 6.19% of ERAS, 6.26% of VOR
Managers holding a meaningful stake in ERAS also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.